Avita Lands Government Contract Worth Up to $25.5 Million to Supply RECELL Products
By Christopher Kuo
Avita Medical entered an agreement worth up to $25.5 million with a research unit of the Department of Health and Human Services to supply the government with treatments for burn mass casualty incidents.
During the 10-year contract, Avita, a wound care company, will grant the Biomedical Advanced Research and Development Authority access to 3,000 units of its RECELL products, which are FDA-approved treatments for thermal burns and trauma wounds, the company said Wednesday.
BARDA is part of the Administration for Strategic Preparedness and Response within the Health Department.
In the event of a burn mass casualty incident, the RECELL products would be deployed to designated centers with trained staff. Avita will also provide BARDA with logistics help, quality assurance and deployment readiness, the company said.
Write to Chris Kuo at chris.kuo@wsj.com
(END) Dow Jones Newswires
April 08, 2026 17:16 ET (21:16 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States